From April 1, 2024 to April 18, 2024, the company has repurchased 2,711,312 shares, representing 0.58% for CLP 42.66 million. With this, the company has completed the repurchase of 6,181,212 shares, representing 1.32% for CLP 100 million under the buyback announced on February 19, 2024.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.8 CNY | +4.89% | +9.00% | -12.19% |
1st Jan change | Capi. | |
---|---|---|
-12.19% | 1.15B | |
-1.89% | 12.5B | |
-9.59% | 7.67B | |
+21.82% | 5.36B | |
-1.31% | 5.26B | |
+0.02% | 4.57B | |
-50.89% | 3.15B | |
+6.42% | 2.59B | |
-10.02% | 2.06B | |
-8.29% | 1.79B |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.